ArticleHealth services research2026
Acute-Care Utilization and Cost Offsets Associated With Language-Concordant, Pharmacist-Integrated Care Management Among High-Need, High-Cost Adults.
Article in Health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo estimate utilization and economic effects of a language-concordant, pharmacist-integrated care-management program and examine equity by language and insurance. STUDY SETTING AND
designWe conducted a retrospective cohort study emulating a target trial across four Phoenix safety-net clinics (March 2022-September 2023) using inverse probability weighting and doubly robust Poisson difference-in-differences. DATA SOURCES AND ANALYTIC SAMPLE: We linked electronic health records, payer claims, health information exchange admission-discharge-transfer alerts, and pharmacist logs for 526 high-need, high-cost adults. Enrollees (n = 263) were matched 1:1 to otherwise eligible usual-care comparators (n = 263) from the same clinics and calendar period. PRINCIPAL
findingsWithin 60 days, hospital admissions (average marginal effect [AME], -0.44; 95% confidence interval [CI], -0.60 to -0.28; incidence-rate ratio [IRR], 0.50 [0.29-0.86]) and emergency department visits (AME, -0.16; 95% CI, -0.27 to -0.05; IRR, 0.47 [0.28-0.77]) were lower. Using standardized 2024 national unit costs and a $470 program cost, estimated net savings were $6421 per enrollee (return on investment [ROI], 13.66:1). Spanish-preferring subgroup estimates were directionally similar, and formal interaction tests were not statistically significant.
conclusionsIn safety-net clinics, this language-concordant, pharmacist-integrated multicomponent program was associated with lower short-term hospital use and substantial near-term standardized cost offsets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.